Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Almac Publishes Breast Cancer Chemotherapy Response Assay

Published: Thursday, February 06, 2014
Last Updated: Wednesday, February 05, 2014
Bookmark and Share
Company announces publication of assay in the Journal of the National Cancer Institute.

Almac’s Diagnostics business unit has announced the publication of its breast cancer chemotherapy response assay in the Journal of the National Cancer Institute (JNCI).

The article entitled “Identification and Validation of an Anthracycline/Cyclophosphamide– Based Chemotherapy Response Assay in Breast Cancer” led by Almac’s Medical Director, Professor Richard Kennedy gives detail on the development and initial validation of a predictive gene signature for chemotherapy response in breast cancer.

Breast Cancer is the world’s most common cancer among women with one in eight diagnosed in their lifetime. Although modern chemotherapy reduces the risk of recurrence for some patients, not everyone benefits. At present there is no means of identifying those patients who will and will not respond to first line therapy.

Almac’s objective in the development of this assay was to provide a means of identifying those breast cancer patients more likely to respond to standard of care chemotherapy treatment.

The assay was developed by Almac in collaboration with Queens University, Belfast and the Mayo Clinic, Rochester, USA. Almac carried out microarray analysis of patient samples and identified a molecular subgroup with a deficiency in DNA damage repair, termed DDRD for DNA Damage Repair Deficient. Almac then developed a 44 gene classifier capable of prospectively identifying this molecular group in patient tumour samples.

The DDRD signature was then initially validated in a neo-adjuvant breast cancer cohort. In the neo-adjuvant setting the assay predicted complete pathologic response with an odds ratio of 3.96, meaning those patients that were DDRD positive were almost four times more likely to respond to treatment compared to patients that were DDRD negative. In the adjuvant setting, a DDRD positive result predicted 5 year relapse free survival with a Hazard Ratio 0.37 compared with test negative patients.

“The publication of this data represents a significant milestone for Almac as we transition this assay into the clinic. The publication of these results combined with our recent out-licensing of the assay to Genomic Health for use in breast cancer patients, highlights the quality of the science being carried out here in Almac” said Professor Paul Harkin, President and Managing Director of Almac’s Diagnostics business unit.

The test has been developed and validated exclusively using formalin fixed paraffin embedded (FFPE) tissue using Almac’s own proprietary Breast Cancer DSA®.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac and Queens University Belfast showcase Northern Irish ‘oncology hub’ to senior Washington DC delegates
The event introduces the Almac led initiative to a US audience of senior pharma, academic and Governmental agencies to encourage strategic collaboration in oncology between the US and Northern Ireland.
Wednesday, March 17, 2010
Gene Expression Study to Develop Prognostic Test for Early Non-Small Cell Lung Cancer
Almac Diagnostics has announced details of a global multi-centre collaborative lung cancer study with leading research organisations in the USA, Canada, Asia and Europe.
Thursday, September 04, 2008
Almac Diagnostics Announces Pioneering Genetic Research on Ductal Carcinoma in Situ
Almac is undertaking a collaborative study with Oxford University to create a gene signature to predict the recurrence of ductal carcinoma in situ.
Thursday, August 09, 2007
Scientific News
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Switch Lets Salmonella Fight, Evade Immune System
Researchers at the University of Illinois at Chicago have discovered a molecular regulator that allows salmonella bacteria to switch from actively causing disease to lurking in a chronic but asymptomatic state called a biofilm.
Genetic Cause of Rare Allergy
Institute has identified a genetic mutation responsible for a rare form of inherited hives induced by vibratory urticaria.
Mitochondria Shown to Trigger Cell Ageing
An international team of scientists has for the first time shown that mitochondria, the batteries of the cells, are essential for ageing.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!